Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Schwab, Luciana P ^a   Peacock, Danielle L ^a   Majumdar, Debeshi ^a   Ingels, Jesse F ^a   Jensen, Laura C ^a   Smith, Keisha D ^a   Cushing, Richard C ^a   Seagroves, Tiffany N ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD133 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOTCH RECEPTOR; VASCULOTROPIN; CASP3 PROTEIN, MOUSE; CASPASE 3; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; HIF1A PROTEIN, MOUSE; KI 67 ANTIGEN; PHOSPHOPROTEIN; TRANSACTIVATOR PROTEIN; TRP63 PROTEIN, MOUSE;

ADENOVIRUS; ALLELE; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL ACTIVITY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EX VIVO STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENETIC TRANSDUCTION; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MOUSE; NONHUMAN; TUMOR CELL; TUMOR GROWTH; TUMOR INITIATING CELL; WILD TYPE; 129 MOUSE; ANIMAL; C57BL MOUSE; CANCER INVASION; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SEPARATION; EPITHELIUM CELL; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE MUTANT; MULTICELLULAR SPHEROID; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; TUMOR VOLUME;

ANIMALS; CASPASE 3; CELL PROLIFERATION; CELL SEPARATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KI-67 ANTIGEN; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PHOSPHOPROTEINS; SPHEROIDS, CELLULAR; TRANS-ACTIVATORS; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84855436875     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3087     Document Type: Article

References (77)

1. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 2009, 9:442-458. 10.2174/156652409788167087, 2752413, 19519402.
2. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008, 8:790-797.
3. Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007, 9:1221-1235. 10.1089/ars.2007.1628, 17536958.
4. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634. 10.1038/onc.2009.441, 2969168, 19946328.
5. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Issacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999, 59:5830-5835.
6. Bos R, Zhong H, Hanrahan CF, Mommers E, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 2001, 93:309-314. 10.1093/jnci/93.4.309, 11181778.
7. Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 2008, 8:60-67. 10.2174/156652408783565568, 18289014.
8. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Børresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47. 10.1371/journal.pmed.0030047, 1334226, 16417408.
9. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C. Overexpression of hypoxia-inducible factor HIF-1α predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005, 116:734-739. 10.1002/ijc.20984, 15849727.
10. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, Woodward WA, Krishnan S, Chang JC, Rosen JM. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2010, 2:55ra79. 10.1126/scitranslmed.3001447, 20980696.
11. Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat 2010, 13:99-108. 10.1016/j.drup.2010.08.001, 20739212.
12. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009, 106:13820-13825. 10.1073/pnas.0905718106, 2720409, 19666588.
13. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161. 10.1016/j.stem.2010.07.007, 20682444.
14. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, Shima H, Johnson RS, Hirao A, Suematsu M, Suda T. Regulation of the HIF-1α level is essential for hematopoietic stem cells. Cell Stem Cell 2010, 7:391-402. 10.1016/j.stem.2010.06.020, 20804974.
15. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513. 10.1016/j.ccr.2009.03.018, 2693960, 19477429.
16. Wang Y, Liu Y, Malek SN, Zheng P. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411. 10.1016/j.stem.2011.02.006, 21474104.
17. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K. mTOR signal and hypoxia-inducible factor-1α regulate CD133 expression in cancer cells. Cancer Res 2009, 69:7160-7164. 10.1158/0008-5472.CAN-09-1289, 19738050.
18. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α oxygen regulation of brain tumor cells. Oncogene 2009, 28:3949-3959. 10.1038/onc.2009.252, 19718046.
19. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008, 13:141-152. 10.1016/j.ccr.2008.01.011, 2262951, 18242514.
20. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 2008, 68:7711-7717. 10.1158/0008-5472.CAN-08-1949, 18829523.
21. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10:R10. 10.1186/bcr1855, 2374965, 18241344.
22. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008, 68:4674-4682. 10.1158/0008-5472.CAN-07-6353, 2459340, 18559513.
23. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.
24. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, Dalerba P, Adorno M, Lobo N, Bueno J, Dirbas FM, Goswami S, Somlo G, Condeelis J, Contag CH, Gambhir SS, Clarke MF. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010, 107:18115-18120. 10.1073/pnas.1006732107, 2964232, 20921380.
25. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003, 163:2113-2126. 10.1016/S0002-9440(10)63568-7, 1892434, 14578209.
26. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
27. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007, 67:563-572. 10.1158/0008-5472.CAN-06-2701, 17234764.
28. Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC. Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res 2007, 13:2168-2177. 10.1158/1078-0432.CCR-06-0918, 17404101.
29. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 2000, 60:4010-4015.
30. Hunter K, Welch DR, Liu ET. Genetic background is an important determinant of metastatic potential. Nat Genet 2003, 34:23-25.
31. Rijnkels M, Rosen JM. Adenovirus-Cre-mediated recombination in mammary epithelial early progenitor cells. J Cell Sci 2001, 114:3147-3153.
32. Ryan HE, Lo J, Johnson RS. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 1998, 17:3005-3015. 10.1093/emboj/17.11.3005, 1170640, 9606183.
33. Seagroves TN, Peacock DL, Liao D, Schwab LP, Krueger R, Handorf CR, Haase VH, Johnson RS. VHL deletion impairs mammary alveologenesis but is not sufficient for mammary tumorigenesis. Am J Pathol 2010, 176:2269-2282. 10.2353/ajpath.2010.090310, 2861092, 20382704.
34. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270. 10.1101/gad.1061803, 196056, 12756227.
35. Hu Y, Smyth GK. ELDA: Extreme Limiting Dilution Analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009, 347:70-78. 10.1016/j.jim.2009.06.008, 19567251.
36. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995, 92:5510-5514. 10.1073/pnas.92.12.5510, 41725, 7539918.
37. Ginouvès A, Ilc K, Macías N, Pouysségur J, Berra E. PHDs overactivation during chronic hypoxia "desensitizes" HIFα and protects cells from necrosis. Proc Natl Acad Sc USA 2008, 105:4745-4750.
38. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006, 281:25903-25914. 10.1074/jbc.M603414200, 3132567, 16847054.
39. Seagroves T, Ryan HE, Lu H, Wouters BG, Knapp AM, Thibault P, Laderoute KR, Johnson RS. The transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001, 21:3436-3444. 10.1128/MCB.21.10.3436-3444.2001, 100265, 11313469.
40. Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, Ceccarelli C, Guarnieri T, Paterini P, Pariali M, Montanaro L, Santini D, Chieco P, Bonafé M. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 2008, 214:25-37. 10.1002/path.2254, 17973239.
41. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008, 105:6392-6397. 10.1073/pnas.0802047105, 2359811, 18427106.
42. Visbal AP, LaMarca HL, Villanueva H, Toneff MJ, Li Y, Rosen JM, Lewis MT. Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated Smoothened. Dev Biol 2011, 352:116-127. 10.1016/j.ydbio.2011.01.025, 21276786.
43. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010, 177:1491-1502. 10.2353/ajpath.2010.091021, 2928980, 20671264.
44. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004, 6:R605-R615. 10.1186/bcr920, 1064073, 15535842.
45. Chen J, Imanaka N, Griffin JD. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 2010, 102:351-360. 10.1038/sj.bjc.6605486, 2816657, 20010940.
46. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, Karsan A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007, 204:2935-2948. 10.1084/jem.20071082, 2118507, 17984306.
47. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res 2003, 63:6130-6134.
48. Seagroves TN, Hadsell D, McManaman J, Palmer C, Liao D, McNulty W, Welm B, Wagner KU, Neville M, Johnson RS. HIF1α is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development 2003, 130:1713-1724. 10.1242/dev.00403, 12620994.
49. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998, 77:640-644. 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8, 9679770.
50. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT, Raman V, Zhen L, Mitzner WA, Sukumar S, Semenza GL. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene
51. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, Ng IO, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 2011, 108:16369-16374. 10.1073/pnas.1113483108, 21911388.
52. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
53. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H. Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 2009, 16:260-267. 10.1007/s12282-009-0150-8, 19701681.
54. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376. 10.1158/1078-0432.CCR-07-1658, 18316557.
55. Sutton LM, Han JS, Molberg KH, Sarode VR, Cao D, Rakheja D, Sailors J, Peng Y. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am J Clinical Pathol 2010, 134:782-787.
56. El Guerrab A, Zegrour R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, Rossignol F, Bignon YJ. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PloS One 2011, 6:e25080. 10.1371/journal.pone.0025080, 3178587, 21966417.
57. Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res 2011, 13:R62. 10.1186/bcr2899, 3218951, 21672245.
58. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2007, 176:19-26. 10.1083/jcb.200604065, 2063618, 17190790.
59. Anderson LH, Boulanger CA, Smith GH, Carmeliet P, Watson CJ. Stem cell marker prominin-1 regulates branching morphogenesis, but not regenerative capacity, in the mammary gland. Dev Dyn 2011, 240:674-681. 10.1002/dvdy.22539, 21337465.
60. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor α in human breast carcinoma. Clinical Cancer Res 2004, 10:8720-8727.
61. Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor α in ZR-75 breast cancer cells. Mol Endocrinol 2002, 16:2231-2242. 10.1210/me.2001-0347, 12351689.
62. Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 2010, 70:4624-4633. 10.1158/0008-5472.CAN-09-3619, 20484027.
63. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928.
64. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417. 10.1016/j.stem.2010.07.010, 20804975.
65. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, Gilmore H, Tung N, Naber SP, Schnitt S, Lander ES, Kuperwasser C. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011, 8:149-163. 10.1016/j.stem.2010.12.007, 3050563, 21295272.
66. van der Groep P, Bouter A, Menko FH, van der Wall E, van Diest PJ. High frequency of HIF-1α overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat 2008, 111:475-480. 10.1007/s10549-007-9817-z, 18030615.
67. Yan M, Rayoo M, Takano EA, Fox SB. BRCA1 tumours correlate with a HIF-1α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br J Cancer 2009, 101:1168-1174. 10.1038/sj.bjc.6605287, 2768103, 19724277.
68. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011, 108:7950-7955. 10.1073/pnas.1102454108, 3093533, 21498687.
69. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644. 10.1016/j.cell.2011.07.026, 21854987.
70. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, Sharma N, Dekoninck S, Blanpain C. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011, 479:189-193. 10.1038/nature10573, 21983963.
71. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005, 9:617-628. 10.1016/j.devcel.2005.09.010, 16256737.
72. Harrison H, Farnie G, Brennan KR, Clarke RB. Breast cancer stem cells: something out of notching?. Cancer Res 2010, 70:8973-8976. 10.1158/0008-5472.CAN-10-1559, 21045140.
73. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, Santini D, Ceccarelli C, Chieco P, Bonafé M. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007, 25:807-815.
74. Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol 2011, 31:4609-4622. 10.1128/MCB.05766-11, 21930782.
75. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008, 10:1433-1443. 2586694, 19048122.
76. Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C, Chen XF, Park S, Ju J, Chen EI. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 2010, 12:R94. 10.1186/bcr2773, 3046435, 21067584.
77. Seagroves TN, Lydon JP, Hovey RC, Vonderhaar BK, Rosen JM. C/EBPβ (CCAAT/enhancer binding protein) controls cell fate determination during mammary gland development. Mol Endocrinol 2000, 14:359-368. 10.1210/me.14.3.359, 10707954.